Fueled by $143M fundraise, Cincy startup doses first patient in new clinical trial

CinCor Pharma Logo

A Cincinnati startup developing treatments for hypertension and other cardio-renal diseases has dosed its first patient in a new clinical trial fueled by a recent $143 million fundraise.

Madisonville-based CinCor Pharma, a clinical-stage biopharmaceutical company, dosed its first patient Thursday in HALO, a phase 2 clinical trial for its lead asset, CIN-107, in patients with uncontrolled hypertension and elevated plasma aldosterone levels.

The double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of CIN-107 after eight weeks of treatment. Overall, CinCor said it plans to enroll 250 patients across 70 sites in the U.S. The first patient was dosed at a study site in Lincoln, Calif.

Click here to read the complete story.

Story excerpt provided by Cincy Inno.

Written by Liz Engel.

Originally published December 10, 2021.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: